Medication use in the neonatal intensive care unit

American Journal of Perinatology

Volumn 31, Issue 9, 2014, Pages 811-821

  Hsieh, Emily M ^a,b   Hornik, Christoph P ^b,c   Clark, Reese H ^d   Laughon, Matthew M ^e   Benjamin, Daniel K ^b,c   Smith, P Brian ^b,c  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Pediatrix Obstetrix Center for Research and Education   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

pharmacotherapy; trends over time

Indexed keywords

AMPICILLIN; AZITHROMYCIN; BERACTANT; CAFFEINE CITRATE; CALFACTANT; CEFOTAXIME; DOPAMINE; DOXAPRAM; ERYTHROMYCIN; FENTANYL; FUROSEMIDE; GENTAMICIN; HYDROCORTISONE; INDOMETACIN; LORAZEPAM; METOCLOPRAMIDE; MIDAZOLAM; MILRINONE; MORPHINE; PARACETAMOL; PHENOBARBITAL; PORACTANT; RANITIDINE; RECOMBINANT ERYTHROPOIETIN; SALBUTAMOL; SILDENAFIL; THEOPHYLLINE; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ARTICLE; DRUG USE; EXTREMELY LOW BIRTH WEIGHT; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN INTENSIVE CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNITED STATES; DRUG THERAPY; DRUG UTILIZATION; NEWBORN; STATISTICS AND NUMERICAL DATA; TRENDS;

DRUG THERAPY; DRUG UTILIZATION; FEMALE; HUMANS; INFANT, NEWBORN; INTENSIVE CARE UNITS, NEONATAL; INTENSIVE CARE, NEONATAL; MALE; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84906791131     PISSN: 07351631     EISSN: 10988785     Source Type: Journal    
DOI: 10.1055/s-0033-1361933     Document Type: Article

References (21)

1. Barr J., Brenner-Zada G., Heiman E., et al. Unlicensed and off-label medication use in a neonatal intensive care unit: A prospective study. Am J Perinatol: 2002; 19 2 67 72
2. Bavdekar S. B., Gogtay N. J. Unlicensed and off-label drug use in children. J Postgrad Med: 2005; 51 4 249 252
3. Pandolfini C., Bonati M. A literature review on off-label drug use in children. Eur J Pediatr: 2005; 164 9 552 558
4. Cuzzolin L., Atzei A., Fanos V. Off-label and unlicensed prescribing for newborns and children in different settings: A review of the literature and a consideration about drug safety. Expert Opin Drug Saf: 2006; 5 5 703 718
5. Conroy S., McIntyre J. The use of unlicensed and off-label medicines in the neonate. Semin Fetal Neonatal Med: 2005; 10 2 115 122
6. Clark R. H., Bloom B. T., Spitzer A. R., Gerstmann D. R. Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics: 2006; 117 6 1979 1987
7. Horen B., Montastruc J-L, Lapeyre-Mestre M. Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol: 2002; 54 6 665 670
8. Moore T. J., Weiss S. R., Kaplan S., Blaisdell C. J. Reported adverse drug events in infants and children under 2 years of age. Pediatrics: 2002; 110 5 e53
9. Kaufman D., Boyle R., Hazen K. C., Patrie J. T., Robinson M., Grossman L. B. Twice weekly fluconazole prophylaxis for prevention of invasive Candida infection in high-risk infants of <1000 grams birth weight. J Pediatr: 2005; 147 2 172 179
10. Manzoni P., Stolfi I., Pugni L., et al. Italian Task Force for the Study and Prevention of Neonatal Fungal Infections; Italian Society of Neonatology. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med: 2007; 356 24 2483 2495
11. Kaufman D. A., Manzoni P. Strategies to prevent invasive candidal infection in extremely preterm infants. Clin Perinatol: 2010; 37 3 611 628
12. Wade K. C., Wu D., Kaufman D. A., et al. National Institute of Child Health and Development Pediatric Pharmacology Research Unit Network. Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother: 2008; 52 11 4043 4049
13. Hibbs A. M., Lorch S. A. Metoclopramide for the treatment of gastroesophageal reflux disease in infants: A systematic review. Pediatrics: 2006; 118 2 746 752
14. U.S. Food and Drug Administration Reglan (metoclopramide) tablets, ODT (orally disintegrating tablets), and injection. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm170934.htm. Accessed July 6, 2012
15. Spitzer A. R., Ellsbury D. L., Handler D., Clark R. H. The Pediatrix BabySteps Data Warehouse and the Pediatrix QualitySteps improvement project system-tools for meaningful use in continuous quality improvement. Clin Perinatol: 2010; 37 1 49 70
16. Clark R. H., Spitzer A. R. Patience is a virtue in the management of gastroesophageal reflux. J Pediatr: 2009; 155 4 464 465
17. Guillet R., Stoll B. J., Cotten C. M., et al. National Institute of Child Health and Human Development Neonatal Research Network. Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics: 2006; 117 2 e137 e142
18. Benjamin D. K. Jr, Stoll B. J., Fanaroff A. A., et al. National Institute of Child Health and Human Development Neonatal Research Network. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics: 2006; 117 1 84 92
19. Van Overmeire B., Smets K., Lecoutere D., et al. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med: 2000; 343 10 674 681
20. Greenough A. Long term respiratory outcomes of very premature birth (<32 weeks). Semin Fetal Neonatal Med: 2012; 17 2 73 76
21. Barst R. J., Ivy D. D., Gaitan G., et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation: 2012; 125 2 324 334